Quantcast

Latest DHA-paclitaxel Stories

2011-07-26 13:52:24

Study uncovers several compounds that inhibit cancer cell invasion, but also reveals that cancer drug paclitaxel does the opposite"”it promotes cancer metastasis. Metastasis"”the spread of cancer from the place where it first started to another place in the body"”is the most common reason that cancer treatments fail. To metastasize, some types of cancer cells rely on invadopodia, cellular membrane projections that act like feet, helping them "walk" away from the primary...

2011-02-23 00:30:00

SEATTLE, Feb. 23, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that updated phase II study results of OPAXIO (paclitaxel poliglumex) in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% (15/40) of the patients receiving OPAXIO in combination with cisplatin and...

2011-01-18 06:30:00

CALGARY, Jan. 18 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, U.S. National Cancer Institute (NCI), which is part of the National Institutes of Health, has agreed to sponsor a 2-Arm randomized Phase II study of carboplatin, paclitaxel plus REOLYSIN((R)) versus carboplatin and paclitaxel alone in the first line treatment of patients with...

2009-10-05 07:00:00

TUSTIN, Calif., Oct. 5 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported additional positive results in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC). Data previously reported from the initial cohort of 21 patients in the study had indicated that 11 of 17 evaluable patients with locally advanced or metastatic NSCLC achieved an objective tumor response...

2009-07-02 06:30:00

CALGARY, July 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that patient enrolment has been completed in the Phase II component of a Phase I/II U.K. trial of REOLYSIN combined with paclitaxel/carboplatin for patients with advanced cancers. The principal investigators for the trial are Dr. Kevin Harrington of The Institute of Cancer Research, London, England, and Dr. Geoff Hall of St. James's Institute of Oncology, Leeds. A total of 30 patients...

2009-03-20 10:59:00

CALGARY, March 20 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced that interim clinical results from its Phase I/II U.K. trial of REOLYSIN(R) combined with paclitaxel/carboplatin for patients with advanced cancers were presented at the Fifth International Meeting on Replicating Oncolytic Virus Therapeutics. The meeting is being held in Banff, Alberta from March 18th to 22nd, 2009. The principal investigator for the trial is Dr. Kevin Harrington of The...

2008-10-20 12:00:31

Peregrine Pharmaceuticals, a clinical stage biopharmaceutical company, has completed enrollment in the first stage of its Phase II trial evaluating a combination regimen of bavituximab with carboplatin and paclitaxel in patients with non-small cell lung cancer. In the trial's Simon two-stage design, 21 patients with non-small cell lung cancer have been enrolled in Stage A of the study. The trial may be expanded to include up to a total of 49 patients if promising results are observed in the...

2008-09-16 12:00:50

Pfizer has announced updated safety and efficacy results from a Phase II, randomized, non-comparative study surrounding its investigational compound, CP-751,871, in patients with non-small cell lung cancer. Results from a Phase II, randomized, non-comparative study showed that 54% of patients with stage III/IV treatment-naive NSCLC receiving the combination CP-751,871 plus carboplatin and paclitaxel (n=97) experienced objective responses. The response rate was 41% in patients treated with...

2008-09-15 12:00:35

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that two-year follow up survival data from its Phase 2b clinical trial in metastatic melanoma were presented at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm. In addition, an integrated safety analysis from Phase 1 and Phase 2 solid tumor trials of elesclomol plus paclitaxel versus paclitaxel alone was presented. Elesclomol is an investigational drug candidate that triggers programmed cell death...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related